Journal article

The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective

Chisa Tsutsumi, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Hiroyoshi Takeuchi, Shinichiro Nakajima, Yoshie Kimura, Yuichiro Tsutsumi, Koichi Ishii, Yasushi Imasaka, Shitij Kapur

Schizophrenia Research | ELSEVIER SCIENCE BV | Published : 2011

Grants

Funding Acknowledgements

This work was funded by Japan Research Foundation for Clinical Pharmacology, Tokyo, Japan (HU), Research Group for Schizophrenia, Tokyo, Japan (HU), Grant-in-Aid for Young Scientists-B from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (HU), Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan (TS), Government of Canada Post-Doctoral Research Fellowships, Ottawa, Canada (TS), Kanae Foundation, Tokyo, Japan (TS) and Mochida Memorial Foundation, Tokyo, Japan (TS).Dr. Uchida has received grants, speaker's honoraria, or manuscript fees from Pfizer Health Research Foundation, GlaxoSmithKline, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Janssen Pharmaceutical, and Pfizer within the past 5 years. Dr. Suzuki has received manuscript fees from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin within the past 5 years. Dr. Takeuchi has received speaker's honoraria or manuscript fees from Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, and Otsuka Pharmaceutical within the past 5 years. Dr. Nakajima has received grants from Pfizer and speaker's honoraria or manuscript fees from Dainippon Sumitomo Pharma, GlaxoSmithKline, Jannsen Pharmaceutical and Pfizer within the past 5 years. Dr. Imasaka has received speaker's honoraria from Eli Lilly, Pfizer, Meiji. GlaxoSmithKline, Janssen Pharmaceutical, and Otsuka within the past 5 years. Dr. Tsutsumi has received consultant fees or speaker's honoraria from Astellas Pharma, Eli Lilly, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Janssen Pharmaceutical, GlaxoSmithKline, and Schering-Plough within the past 5 years. Dr. Watanabe has received grants, or consultant fees from Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, and Pfizer, and received speaker's honoraria from Astellas Pharma, Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji, Otsuka Pharmaceutical, Pfizer, and Yoshitomiyakuhin within the past 5 years. Dr. Kapur has received grant support from AstraZeneca and GSK; and has served as consultant and/or speaker for AstraZeneca, Bioline, BMS-Otsuka, Eli Lilly, Janssen (J&J), Lundbeck, NeuroSearch, Pfizer, Roche, Servier and Solvay Wyeth. Other authors have nothing to disclose.